Roche signs USD 2.8bn Alnylam deal for hypertension drug
A high blood pressure treatment will be the focus of a partnership between Roche and Alnylam.
By Naomi Kresge, Bloomberg
Roche Holding AG will work together with Alnylam Pharmaceuticals Inc. on a potential treatment for high blood pressure in a deal worth as much as USD 2.8bn, expanding the Swiss company’s footprint beyond the cancer therapies that long anchored its business.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
